In recent years scientific developments have led to a surge of activity in regenerative medicine, that is attempts to extend life span using biotechnology. Oxford Economics predicts that within a decade the regenerative marketplace will grow to $20 billion annually. From tissue engineering, to halting the biological processes of ageing with stem cells and gene therapy, and applying machine learning to biological data, many claims are being made about the next big thing in ageing but when will they appear? We will hear from those researchers at the forefront of the science of ageing about what will wind back the clock and when we will see its impact.

Brain K. Kennedy, president and chief executive, Buck Institute for Research on Aging
J. Craig Venter, co-founder, executive chairman and chief executive, Human Longevity Inc.
Matt Kaeberlein, professor of pathology and adjunct professor of genome sciences, University of Washington

Moderator: Natasha Loder, health-care correspondent, The Economist